Aaron founded Genomic Vision in 2005 and was appointed as the company’s President and Chief Executive Officer in May 2006. He also serves as Genomic Vision’s Chief Scientific Officer.
Aaron has brought more than 20 years of scientific and management experience to Genomic Vision and is responsible for the overall planning and execution of the company’s operations. He also facilitates and coordinates research collaborations and licensing and business agreements between Genomic Vision and other industry leaders and supervises trademark and patent activities.
Aaron co-discovered Molecular Combing and is a renowned expert on all aspects of this pioneering technology including its applications. His contributions to this field have been published extensively in leading medical and business journals and he has authored more then 20 patent applications that have been granted on Molecular Combing
Prior to Genomic Vision he spent 15 years in a permanent position at the Pasteur Institute in Paris where he was Head of the Genome Stability Unit. Aaron received the Jacques Monod prize from the Fondation de France (an award to young scientists who have made significant advances in the early years of their career). Formerly, he pursued post-doctoral research in Prof. Jean-Pierre Changeux’s laboratory, Pasteur Institute, Paris, where he was awarded a Human Frontier Science Fellowship. Aaron received his Ph.D. from the Weizmann Institute of Science, Israel in 1993.
With over 20 years of professional experience in the field of finance and biotechnologies, Erwan Martin is an expert on financial issues and corporate development.
He joined Genomic Vision is 2009 as Administrative and Financial Director, before being appointed Vice-president of finance and corporate development in 2011.
As well as the administrative and financial management of the company and the search for capital (fund raising), today he is in charge of negotiating collaboration agreements and licenses with industrial and academic partners and industrial production contracts. He also oversees internal industrialization and quality control.
Erwan Martin started his career as an analyst, and was head of missions for ten years with Syndex, a firm specializing in audits and consultancy for works councils.
In 2000, he co-founded Cytomics Pharmaceuticals, a biotechnology company specialising in drug research. A member of the board and in turn General Manager and Administrative and Financial Director, he supervised the development of the company, in particular organising several funding rounds and mobilizing over €20 million in public aid.
Erwan Martin holds an MBA from the Warwick Business School (United Kingdom). He is also a graduate of the Ecole Supérieure de Commerce (ESC) in Toulouse.
A physicist by training with more than ten years’ experience, Yamina Ghomchi specializes in complex instrumentation.
She joined Genomic Vision in 2006 as a project manager for R&D Instrumentation, before taking responsibility for the Department of Technology & Innovation.
Today, she is in charge of designing and developing specific imaging technologies and automating the molecular biology process.
Yamina Ghomchi started her career in 1997 at the Meudon Observatory, as part of her doctoral thesis, as a research engineer in the Laboratory for space studies and astrophysics instrumentation (LESIA), where she helped to develop an instrument for the ESA Rosetta space mission.
She then joined Atmel Grenoble, as a Test & Characterisation engineer, and worked as a consultant for Segime (Altran group) on missions in the field of high-precision optics systems.
She is a graduate engineer from the ENSPS (Ecole Nationale Supérieure de Physique de Strasbourg) and a doctor of physics (Astrophysics and associated Instrumentations) of the University of Paris-VI.
With over 20 years of professional experience in both the biotechnology and venture capital investment sectors, Jonathan Hanley joined Genomic Vision in 2013, bringing to the company a broad knowledge of the healthcare industry from a research, management and venture capital perspective.
A member of the R&D executive board at Genomic Vision, Jonathan Hanley supervises technology transfer and expertise to clients and partners, as well as looking for new avenues for development.
A biologist and biophysicist by trade, Jonathan graduated in biology at Portsmouth University before getting a PhD in biophysics at the University College London and a MBA at the Ecole Nationale des Ponts et Chaussées in Paris.
After starting his career as a research scientist at CEA-Saclay in 1993, he joined the private sector five years later, working for Transgenomic Inc. as a product scientist. In 2000, he was recruited as director of functional proteomics at Genodyssee, where he was responsible for the development strategy of protein biopharmaceuticals . In 2002, he joined the National Physics Laboratories (NPL-Serco), in London, to become head of biotechnology, managing a research team of 10 scientists.
With an expertise in biotech and finance/management, he brought his career to a new level, working from 2005 to 2011 as an investment manager and biotechnology analyst at Amundi (formerly Société Générale Asset Management), a venture capital fund investing in biotech and pharma.